Members of our leadership team are looking forward to presenting at both the H.C. Wainwright & Co., LLC Third Annual Kidney Virtual Conference and JonesTrading’s JonesHealthcare Seaside Summit next week! During the presentations, the team will share new analyses from the third cohort of patients in our ongoing Phase 1b trial of RGLS8429 for those living with #ADPKD. Learn more: https://lnkd.in/e5K2FXsy
About us
Regulus Therapeutics Inc. (Nasdaq:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is located in San Diego, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus' scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research.
- Website
-
http://www.regulusrx.com
External link for Regulus Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, CA
- Type
- Public Company
- Founded
- 2007
- Specialties
- microRNA and great company culture
Locations
-
Primary
Get directions
San Diego, CA 92121, US
Employees at Regulus Therapeutics
Updates
-
Today our Associate Director of Translational Medicine Tania Valencia is presenting at the ProteiNext 2024: Extracellular Vesicles Symposium! If you’re attending, be sure to check out her session, “Urinary Exosomal Polycystins as Biomarkers for Autosomal Dominant Polycystic Kidney Disease”, on Wednesday, June 12 at 3:25pm ET. Learn more and register for the event here: https://lnkd.in/ejFswwzU
-
-
Members of our team are excited to be in Stockholm this week for the European Renal Association (ERA) Congress and look forward to meeting with and learning from peers in the #nephrology space. If you’re interested in hearing more about Regulus’ work in kidney diseases, including autosomal dominant polycystic kidney disease, please reach out, we’d love to connect! #ERA24 #ADPKD
-
-
Today is International Clinical Trials Day and our team is taking the day to recognize the individuals who participate in and facilitate clinical trials, both in our work in autosomal dominant polycystic kidney disease here at Regulus and all trials around the world. Thank you! #ClinicalTrialsDay #CTD2024 #ADPKD
-
-
Today we announced our first quarter financial results and recent updates. Read more: https://lnkd.in/eBSpXKj5 $RGLS
-
-
We are thrilled to announce that we’ve advanced to the fourth and final cohort of our Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (#ADPKD). Learn more about this update and the next steps in our work to bring this potential treatment to patients: https://lnkd.in/eBnxDFum
-
-
Here at Regulus, our constant focus is on bringing life changing therapies to patients living with orphan kidney diseases including autosomal dominant polycystic kidney disease (#ADPKD). This is why we’re honored to recognize #NationalKidneyMonth this March, keeping patients and their caregivers at the forefront of our minds.
-
-
Today we announced our fourth quarter and year end financial results and recent updates. Read more: https://lnkd.in/ekzfty6U $RGLS
-
-
This morning, we were excited to share positive topline data from our second cohort of patients in our Phase 1b MAD Study of RGLS8429 in autosomal dominant polycystic kidney disease. We’d like to extend a huge shout out to our team who’s been hard at work on the study, and a thank you to the patients participating, without whom none of this would be possible. Read the full announcement and results here: https://lnkd.in/ePiUNTg3 #ADPKD $RGLS
-